Promotion unit

The Eugène Marquis Centre oversees every stage of its clinical trials, from concept design to the publication of results. The Centre helps design the study, obtain funding and the necessary authorisation and ensure that trials are conducted correctly so as to achieve reliable, reproducible results. To help in those tasks, the Centre established the promotion unit in 2013.

Clinical trials are conducted across all departments of the Centre not only in collaboration with doctors, but also, following the example of its Scientific Steering Committee (CoPilS) [Comité de Pilotage Scientifique], with the participation of all healthcare providers, including doctors, pharmacists and paramedical staff (nurses, technicians and physicists). Clinical trials cover all care sectors, from drug therapy to innovative techniques (adaptive radiotherapy, radioembolisation, etc.), as well as support services and the implementation of innovative practices, such as outpatient care.

Organisational Chart – Promotion Unit

Dr Thierry LESIMPLE – Clinical Research Director

Oussama ZEKRI – Head of Clinical Research

Dr Boris CAMPILLO-GIMENEZ – Methodologist–Biostatistician

Martine GESTIN – Project Supervisor

Camille JOUANNY – Clinical Research Assistant

Marion TROCHET – Clinical Research Assistant

Guillaume DANTON – Data Manager

Isabelle AUFFRAY – Clinical Research Assistant


    • Does adaptive radiotherapy in head and neck cancer decrease xerostomia ?, ESMO – ECCO – ESTRO, Amsterdam, Netherland September 2013
    • Anatomical markers of parotid overdosage within the course of locally advanced head and neck IMRT guiding an adaptive RT strategy, ESTRO 33th, Vienne, Austria, April 2014.
    • Impact of weekly re-planning to spare the parotid glands in head and neck cancer radiotherapy, ASTRO 56th, San Francisco, USA, September 2014.
    • Nomograms to assess the parotid gland dose in head and neck IMRT based on anatomical markers, ESTRO 3rd Forum, Barcelona, Spain, April 2015.
    • Evaluation of deformable image registration methods for dose monitoring in head and neck adaptive radiotherapy, ESTRO 3rd Forum, Barcelona, Spain, April 2015.
    • Nomogramme pour prédire le surdosage parotidien au cours d’une RCMI pour cancers ORL, 26ème congrès de la SFRO, Paris, France, Octobre 2015.
    •  Stratégie optimale de radiothérapie adaptative dans les cancers ORL localement avancés, 26ème congrès de la SFRO, Paris, France, Octobre 2015.
    • Cellules immunitaires circulantes chez les patients atteints d’un glioblastome ou gliome mixte anaplasique en rechute traité par Bevacizumab – recherche d’un lien avec la réponse au traitement – Congrès ANOCEF, Bruxelles, Belgique, Juin 2016


    • Castelli J, Simon A, Louvel G, Henry O, Chajon E, Nassef M, Haigron P, Cazoulat G, Ospina JD, Jegoux F, Benezery K, de Crevoisier R. Impact of head and neck cancer adaptive radiotherapy to spare the parotid glands and decrease the risk of xerostomia. Radiat Oncol. 2015 Jan 9;10:6.
    • Zhang P, Simon A, Rigaud B, Castelli J, Ospina Arango JD, Nassef M, Henry O, Zhu J, Haigron P, Li B, Shu H, De Crevoisier R. Optimal adaptive IMRT strategy to spare the parotid glands in oropharyngeal cancer. Radiother Oncol. 2016 Jul;120(1):41-7.
    • Castelli J, Simon A, Rigaud B, Lafond C, Chajon E, Ospina JD, Haigron P, Laguerre B, Loubiere AR, Benezery K, de Crevoisier R. A Nomogram to predict parotid gland overdose in head and neck IMRT. Radiat Oncol. 2016 Jun 8;11:79.